Year: 2022

Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid Tumor Models Upcoming clinical data presentations at SITC and SNO Annual Meetings Virtual R&D Day on December 6, 2022, with Candel leadership and renowned oncology expertsNEEDHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. “Candel made important progress across multiple facets of the organization this quarter,” said Paul Peter Tak, MD, PhD,...

Company maintains strong cash position of $195.4 million SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter and nine months ended September 30, 2022. “Our focus remains on executing and advancing both our inflammation and oncology programs. In our RPT193 program, we are actively enrolling our Phase 2b clinical trial in patients with moderate-to-severe atopic dermatitis, and we remain on track to initiate a Phase 2a clinical trial in asthma in the first quarter of next year,” said Brian Wong, M.D., Ph.D., President...

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the third quarter ended September 30, 2022 and provided a corporate update. Chris Seto, CEO of Spectral Medical, commented, “We are making steady headway with our Tigris trial, a Phase III clinical trial evaluating PMX for endotoxemia and septic shock. We are witnessing stable recruitment levels across our Tigris clinical trial sites with 48 patients now enrolled out of the 150 total patients to be enrolled in the trial. We are...

OREM, Utah, Nov. 10, 2022 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, today announced financial results for the third quarter of 2022. “Increased cost of goods, increased shipping costs, delivery delays, and parts availability hit Reflect hard in the third quarter. Having said that, we are in a strong cash position to weather this downturn in revenue and anticipate a strong finish to the year. Our marketing efforts are continuing as we seek to expand market penetration and sales. Reflect will be exhibiting at the world’s largest cannabis show in Las Vegas this month. This should be a very lucrative show for us. On the new business front we are working with a current customer to install 5-10 freezer units...

HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S. Securities and Exchange Commission. “Following the receipt of a favorable decision from the Institutional Review Board of the lead clinical site for the OPMD Natural History Study in the United States and the formal completion of the Site Initiation Visit at this key clinical enrollment site, the screening of OPMD subjects for...

On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 and LABP-104,” said Gregory Oakes, President and CEO of Landos. “In August, we announced positive top-line results from our NX-13 Phase 1b trial, which showed a favorable safety and tolerability profile in ulcerative colitis (UC) patients across a range of doses, as well as promising early efficacy signals. We continue to believe in NX-13’s...

LONDON and HONG KONG, Nov. 10, 2022 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September 30, 2022. Third Quarter 2022 and Recent Highlights:Reported third quarter 2022 revenue of US$80 million Reported loss from operations of US$9 million, adjusted earnings1 of US$21 million and adjusted EBITDA2 of US$27 million in the third quarter Achieved gross margin of 59% in the third quarter Appointed Professor Robert Harris, founder and former CEO of Lakeside Healthcare Group, one of UK’s largest GP practices, as Executive Chairman of Prenetics EMEA Ended the third quarter with cash and other short-term assets3 of approximately US$250 million Obtained HSBC banking...

– SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS – – Selected development candidate for program to treat GPC3-expressing solid tumors including HCC, SENTI-301A; expected IND filing in 2023 – – Preclinical data from two solid tumor CAR-NK programs highlighted at SITC – – Cash position of $114.9 million as of September 30, 2022; maintain expectation of cash runway into 2024 – SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today reported financial results for the third quarter ended September...

Book Value per Share of $11.75 as at September 30, 2022 TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX: STCK and STCK.WT) today announced its financial results for the three and nine months ended September 30, 2022. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary (as at September 30, 2022):Book Value per Share of the Company was $11.75, as compared with $11.25 as at September 30, 2021, a 4% increase.The Company’s cash position was $43.2 million, or $4.68 per share.To date, the Company has completed seven investments valued at $65.3 million or $7.08 per share“We continue to diligently evaluate companies to add to our portfolio that we believe are market leaders with strong growth potential,” said Jeff Parks, CEO...

– Recently presented preclinical data support potential benefits of next-generation Duchenne gene therapy candidate SGT-003; program on track for mid-2023 Investigational New Drug (IND) submission – – Company ends Q3 with approximately $142.2 million in cash and investments; anticipated cash runway into Q2 2024 – – Company expects to close acquisition of AavantiBio and $75 million Private Placement by year-end, resulting in broader pipeline of neuromuscular and cardiac genetic medicines and anticipated cash of $215 million to support company to important milestones and into 2025 – CHARLESTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported...